Sunshine Biopharma Inc. (SBFMW) stock
SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.03+0.00 (+2.00%)
Close on Oct 30, 2026Market cap $11.36MP/E –Yield –
Sunshine Biopharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Sunshine Biopharma's ebitda for the twelve months ending Jun 30, 2026 was -$5.54M. For fiscal 2025 it was -$5.89M. The highest annual figure on record is -$562.81K in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.89M | – |
| FY2024 | Dec 31, 2024 | -$5.59M | – |
| FY2023 | Dec 31, 2023 | -$4.64M | – |
| FY2022 | Dec 31, 2022 | -$26.98M | – |
| FY2021 | Dec 31, 2021 | -$2.43M | – |
| FY2020 | Dec 31, 2020 | -$562.81K | – |
| FY2019 | Dec 31, 2019 | -$627.86K | – |
| FY2018 | Dec 31, 2018 | -$1.11M | – |
| FY2017 | Dec 31, 2017 | -$850.56K | – |
| FY2016 | Dec 31, 2016 | -$932.38K | – |
| FY2015 | Dec 31, 2015 | -$776.03K | – |
| FY2014 | Dec 31, 2014 | -$1.76M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.32M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$990.36K | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.23M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.22M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.31M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$742.27K | – |
| Q2 FY2023 | Jun 30, 2023 | -$979.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$23.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$693.51K | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -$276.45K | – |
| Q3 FY2021 | Sep 30, 2021 | -$493.08K | – |
| Q2 FY2021 | Jun 30, 2021 | -$385.41K | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.27M | – |
| Q4 FY2020 | Dec 31, 2020 | -$339.76K | – |
| Q3 FY2020 | Sep 30, 2020 | -$63.79K | – |
| Q2 FY2020 | Jun 30, 2020 | -$125.40K | – |
| Q1 FY2020 | Mar 31, 2020 | -$33.87K | – |
| Q4 FY2019 | Dec 31, 2019 | -$247.12K | – |
| Q3 FY2019 | Sep 30, 2019 | -$199.17K | – |
| Q2 FY2019 | Jun 30, 2019 | -$62.78K | – |
| Q1 FY2019 | Mar 31, 2019 | -$105.73K | – |
| Q4 FY2018 | Dec 31, 2018 | -$137.61K | – |
| Q3 FY2018 | Sep 30, 2018 | -$285.64K | – |
| Q2 FY2018 | Jun 30, 2018 | -$576.82K | – |
| Q1 FY2018 | Mar 31, 2018 | -$159.96K | – |
| Q4 FY2017 | Dec 31, 2017 | -$160.41K | – |
| Q3 FY2017 | Sep 30, 2017 | -$109.97K | – |
| Q2 FY2017 | Jun 30, 2017 | -$471.71K | – |
| Q1 FY2017 | Mar 31, 2017 | -$108.47K | – |
| Q4 FY2016 | Dec 31, 2016 | -$320.54K | – |
| Q3 FY2016 | Sep 30, 2016 | -$101.05K | – |